Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells

Limited therapeutic options are available for advanced-stage hepatocellular carcinoma owing to its poor diagnosis. Drug resistance to sorafenib, the only available targeted agent, is commonly reported. The comprehensive elucidation of the mechanisms underlying sorafenib resistance may thus aid in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chih-Ta, Liao, Li-Zhu, Lu, Ching-Hui, Huang, Yung-Hsuan, Lin, Yu-Kie, Lin, Jung-Hsin, Chow, Lu-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156679/
https://www.ncbi.nlm.nih.gov/pubmed/32203105
http://dx.doi.org/10.1038/s12276-020-0404-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156679/
https://www.ncbi.nlm.nih.gov/pubmed/32203105
http://dx.doi.org/10.1038/s12276-020-0404-2

Ejemplares similares